HCC
DGX icon

Hirtle Callaghan & Co’s Quest Diagnostics DGX Stock Holding History

Hirtle Callaghan & Co’s Portfolio DGX Stock Details DGX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2015
Q1 		– Sell
-120
Closed -$8K – 108
2014
Q4 		$8K Hold
120
– – ﹤0.01% 438
2014
Q3 		$7K Hold
120
– – ﹤0.01% 485
2014
Q2 		$7K Hold
120
– – ﹤0.01% 523
2014
Q1 		$7K Hold
120
– – ﹤0.01% 507
2013
Q4 		$6K Hold
120
– – ﹤0.01% 493
2013
Q3 		$7K Buy
+120
New +$7.18K ﹤0.01% 495

Other funds holding DGX

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Macquarie Group
Macquarie Group Sydney, NSW 2000, Australia $23.2B AUM 40.19% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
BA
BlackRock Advisors Wilmington, Delaware $98.8B AUM 15.8% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
DSA
Davis Selected Advisers Tucson, Arizona $23.3B AUM 26.95% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return
American Century Companies
American Century Companies Kansas City, Missouri $226B AUM 44.75% 1-Year Est. Return
Boston Partners
Boston Partners Boston, Massachusetts $113B AUM 38.87% 1-Year Est. Return

Hirtle Callaghan & Co's DGX Position: Q1 2015 in Review

Hirtle Callaghan & Co sold out of Quest Diagnostics (DGX) in Q1 2015, closing a stake of 120 shares — an estimated $8K sold.

Hirtle Callaghan & Co first reported a position in DGX in Q3 2013 and held it in 6 quarters. The position peaked at $8K in Q4 2014. 553 funds tracked by Wall St. Rank hold DGX as of Q1 2015.

  • Hirtle Callaghan & Co reported no remaining Quest Diagnostics position as of Q1 2015 after selling out during the quarter.
  • Hirtle Callaghan & Co sold 120 Quest Diagnostics shares in Q1 2015, an estimated $8K.
  • Hirtle Callaghan & Co first reported a position in Quest Diagnostics in Q3 2013 and held it in 6 quarters.
  • Hirtle Callaghan & Co's Quest Diagnostics position peaked at $8K in Q4 2014.
  • 553 funds tracked by Wall St. Rank held Quest Diagnostics as of Q1 2015.

Based on Hirtle Callaghan & Co's 13F filing for Q1 2015, filed 15 May 2015.